Brandon W. Fenn

Brandon represents companies at all stages of their life cycle, with a focus on companies in the life sciences and technology spaces. He has substantial experience representing companies and investors in connection with initial public offerings and other capital markets transactions, venture capital financings, and M&A transactions. Brandon regularly advises his clients on general corporate matters, both in the private and public spaces, as well as public companies governance and reporting.

Some of Brandon’s recent representative transactions include advising:

Capital markets

• VectivBio Holding AG on its $146.6 million IPO and $125.3 million follow-on offering
• Immunovant on its $74 million follow-on offering
• Molecular Partners AG on its $63.8 million IPO
• DigitalOcean Holding on its $775.5 million IPO
• Olo on its $517.5 million IPO
• Keros on its $110 million IPO
• Neuronetics on its $138 million IPO

M&A

• Oyster Point Pharma on its $415 million sale to Viatris
• Therachon on its up to $910 million sale to Pfizer
• VectivBio on its sale to Ironwood for $1 billion, net of cash and debt
• Plated on its sale to Albertsons

Private financing

• MANTL on its $19 million Series A financing and $75.2 million Series B financing
• Tourmaline Bio on its $75 million private placement and $112 million Series A financing
• SalioGen Therapeutics on its $115 million Series B financing
• The investors in A24 Films’ $225 million financing
• The investors in LI.FI’s $17.5 million Series A financing
• The investors in Scipher Medicine’s $110 million Series D financing
• Thrasio on its $260 million Series C financing